LH
Labcorp Holdings Inc.
LH's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over LH overall, supported by stronger modeled upside and stronger valuation.
LH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
LH's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $136 | -63% |
| Forward | 19x | $372 | — |
| Fair | 24x | $296 | -20% |
| Current | 31x | $372 | — |
| Expensive | 41x | $500 | +34% |
Historical ranges are pointers, not guarantees.
LH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LH, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LH on the outlook, with more favorable profitability expectations.
LH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.25 | +58% |
| Q3 2026 | $12.19 | +20% |
| Q2 2026 | $12.09 | +33% |
| Q1 2026 | $11.29 | +30% |
| Q4 2025 | $10.46 | +18% |
| Q3 2025 | $10.20 | +94% |
| Q2 2025 | $9.08 | +69% |
| Q1 2025 | $8.67 | +71% |
| Q4 2024 | $8.84 | +85% |
LH's earnings per share have fallen from their peak: $12.19 over the past year, against $29.36 in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LH on earnings, with stronger typical year-over-year growth.
LH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +6.9% |
| Q2 2026 | $3.7B | +5.8% |
| Q1 2026 | $3.5B | +5.8% |
| Q4 2025 | $3.5B | +5.6% |
| Q3 2025 | $3.6B | +8.6% |
| Q2 2025 | $3.5B | +9.5% |
| Q1 2025 | $3.3B | +5.3% |
| Q4 2024 | $3.3B | +9.8% |
LH's revenue has grown year over year for 10 quarters in a row: $3.8B last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -0.6 points |
| Q2 2026 | 12% | +0.9 points |
| Q1 2026 | 11% | +1 points |
| Q4 2025 | 7.6% | +1.1 points |
| Q3 2025 | 11% | +3.4 points |
| Q2 2025 | 11% | +2 points |
| Q1 2025 | 9.8% | -0.4 points |
| Q4 2024 | 6.5% | +11 points |
LH's operating margin was 11% last quarter, down 0.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LH on profitability, with a higher operating margin.
LH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $412.2M | +47% |
| Q2 2026 | $313.9M | -42% |
| Q1 2026 | $70.5M | +$178M |
| Q4 2025 | $490.3M | -26% |
| Q3 2025 | $280.5M | +74% |
| Q2 2025 | $542.7M | +25% |
| Q1 2025 | -$107.5M | +$56.1M |
| Q4 2024 | $665.1M | +61% |
LH still generates free cash flow, though less than at its 2021 peak: $1.3B over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
LH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -400K shares |
| 1 year | -2.5% | -2.1M shares |
| 3 years | -6.2% | -5.4M shares |
| 5 years | -16% | -15.5M shares |
| Available history | -17% | -17M shares |
LH has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $353.8M |
| Q1 2026 | $98M |
| Q4 2025 | $225M |
| Q3 2025 | $25M |
| Q4 2024 | $75.1M |
| Q3 2024 | $75M |
| Q4 2023 | $9M |
LH spent $677M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 2.8x | Moderate |
LH's net debt is about 2.5 years of its operating earnings (EBITDA), up from 2.2 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over LH on leverage, with a lower net debt burden relative to earnings.
LH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.6 | Overbought |
| Stochastic | 91.4 | Overbought |
LH's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LH PE vs Healthcare Sector
| Metric | LH | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 26x | 18% above |
| PE % | 77 | 29 | 48 pts above |
LH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $334.7 | 11% above |
| 20 week MA | $319.9 | 16% above |
| 50 week MA | $286.8 | 30% above |
| 100 week MA | $270.3 | 38% above |
| 200 week MA | $240.9 | 55% above |
LH is in an uptrend: it's above all five of its weekly moving averages, and 55% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
LH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.5 | $175.1 | +20% |
| 2021 | $175.1 | $259.4 | +48% |
| 2022 | $259.4 | $199.0 | -23% |
| 2023 | $199.0 | $227.3 | +14% |
| 2024 | $227.3 | $230.4 | +1.4% |
| 2025 | $230.4 | $253.9 | +10% |
| 2026 YTD | $253.9 | $372.3 | +47% |
LH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.